Health Canada Approves Symdeko to Treat CF Patients 12 and Up with Certain Gene Mutations
People ages 12 and older with cystic fibrosis (CF) who live in Canada can now be treated with Vertex Pharmaceuticals’ Symdeko (tezacaftor/ivacaftor and ivacaftor). This follows Health Canada‘s approval of Symdeko to treat people who have two copies of the F508del mutation in the CFTR…
